Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 27, 2022 for Docon Technologies Pvt Ltd Thyrocare Technologies Ltd - 539871 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 27, 2022 for Docon Technologies Pvt Ltd Thyrocare Technologies Ltd - 539871 - Clarification Sought By BSE On "Spurt In Volume Of Shares Traded"
With reference to your letter No. L/SURV/ONL/PV/RS/ 2022-2023 / 75 dated 07-06-2022 sent to us by mail, we wish to reply as follows: 1. We have been disclosing all the events / information as per Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 2. There is no information /details or any impending announcement, which may have a bearing on the volume behavior of the Script, and which have not been disclosed. 3. You will agree that such spurt or dip in the volume has become a regular feature not only in our script but also in almost all the scrips. Thyrocare Technologies Ltd - 539871 - Clarification sought from Thyrocare Technologies Ltd
The Exchange has sought clarification from Thyrocare Technologies Ltd on June 7, 2022, with reference to Movement in Volume.The reply is awaited. Thyrocare recasts image to reflect more than just thyroid-testing
To build diagnostic presence in hospitals, and partner with pharmacy counters Thyrocare Technologies Ltd - 539871 - Clarification Sought By BSE On "Spurt In Volume Of Shares Traded"
With reference to your letter No. L/SURV/ONL/PV/MS/ 2022-2023 / 67 dated 27-05-2022 sent to us by mail, we wish to reply as follows: 1. We have been disclosing all the events/information as per Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 2. There is no information /details or any impending announcement, which may have a bearing on the volume behavior of the Script, and which have not been disclosed. 3. You will agree that such spurt or dip in the volume has become a regular feature not only in our script but also in almost all the scrips. Thyrocare Technologies Ltd - 539871 - Clarification sought from Thyrocare Technologies Ltd
The Exchange has sought clarification from Thyrocare Technologies Ltd on May 27, 2022, with reference to Movement in Volume.The reply is awaited. Thyrocare Technologies Ltd - 539871 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the Financial Year ended March 31, 2022. Thyrocare Technologies Ltd - 539871 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyThyrocare Technologies Ltd 2CIN NO.L85110MH2000PLC123882 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Ramjee Dorai Designation: Company Secretary and Compliance Officer EmailId: ramjee.d@thyrocare.com Name of the Chief Financial Officer: Sachin Salvi Designation: Chief Financial Officer EmailId: sachin.salvi@thyrocare.cpm Date: 14/05/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Thyrocare Technologies Ltd - 539871 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Thyrocare Technologies Ltd 2 CIN NO. L85110MH2000PLC123882 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* NA 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)NA Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Ramjee DoraiDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Sachin Salvi Designation : -Chief Financial Officer Date: 14/05/2022